Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 04:27 pm IST
Share
Chemclin Diagnostics Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 120.88 million compared to CNY 120.22 million a year ago. Revenue was CNY 120.88 million compared to CNY 120.22 million a year ago. Net income was CNY 39.11 million compared to CNY 38.14 million a year ago. Basic earnings per share from continuing operations was CNY 0.1 compared to CNY 0.11 a year ago. Diluted earnings per share from continuing operations was CNY 0.1 compared to CNY 0.11 a year ago.
Chemclin Diagnostics Co Ltd is a China-based company mainly engaged in the research and development of clinical immuno chemiluminescence diagnostic test reagents and instruments. The Company's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The Company mainly operates its businesses in the domestic market.